search
Back to results

Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors

Primary Purpose

Endometrial Cancer, Obesity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dietary Intervention
Informational Material
Dietary Education
Weight Maintenance
Average score of Obesity and Weight-Loss Quality of Life Questionnaire
Sponsored by
Case Comprehensive Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Endometrial Cancer focused on measuring endometrial cancer, survivor, obesity, diet, high protein, protein-sparing modified fast intervention, PSMF

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Previous diagnosis of endometrial cancer, successfully treated through surgery
  • Body mass index (BMI) > 30 kg/m^2
  • > 8 weeks removed from surgery to treat endometrial cancer

Exclusion Criteria:

  • No previous diagnosis of endometrial cancer
  • BMI < 30 kg/m^2
  • Any history of cardiovascular, kidney, or liver disease
  • Using medication to treat diabetes
  • History of cardiac arrhythmias
  • Inability to comply with follow up regimen
  • Inability to read or speak English
  • Abstention from meat and other animal products

Sites / Locations

  • Cleveland Medical Center, University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center
  • MetroHealth Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Supportive Care (PSMF)

Arm Description

Participants will take part in a Protein-Sparing Modified Fast (PSMF) Intervention for weight loss. Participants will undergo a dietary intervention high in protein for 6 weeks or until they have loss 15% of their body weight. This intervention will be followed by weight maintenance in which participants reintroduce non-starchy vegetables to their diet. At this time participants will also receive informational material and dietary education which teaches participants how to read nutrition labels and calculate carbohydrate loads in foods. Participants are given the Obesity and Weight-Loss Quality of Life Questionnaire to survey the impact of the intervention

Outcomes

Primary Outcome Measures

Mean Weight loss assessed with the digital scale
Mean weight loss will be presented as mean total weight loss in kilograms from baseline
Mean Weight loss assessed with the digital scale
Mean Weight loss will be presented as mean total weight loss in kilograms from baseline.

Secondary Outcome Measures

Changes in levels of total cholesterol
Average differences in total cholesterol between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Changes in levels of markers of inflammation (C-reactive protein)
Average differences in C-reactive protein between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Changes in levels of glucose
Differences in glucose levels between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Number of drop-out participants
Presented as the difference in the number of participants who completed the study from the number of participants enrolled at baseline. This is reported as one of the markers of feasibility.
Average percentage of positive urinary ketone tests as a marker of dietary adherence
Assessed using the presence of urinary ketones beginning on day four of the intervention. Adherence rates will be presented as the percentage of positive urinary ketone tests for the duration of the intervention.
Number of Participant with reported side effects
Adverse events will be recorded by participants on a daily basis. Number of participants with related adverse events will be reported as one of the measures of feasibility
Changes in quality-of-life as assessed by the Obesity and Weight Loss Quality-of-Life Questionnaire
The difference between mean quality of life scores at the two time points will be assessed using a one-sided anova test with statistical significance set at p < 0.05.
Changes in levels of markers of inflammation (interleukin 6)
Average differences in interleukin 6 between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Changes in levels of markers of inflammation (tumor necrosis factor - alpha)
Average differences in tumor necrosis factor - alpha between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Changes in levels of markers of inflammation (leptin)
Average differences of leptin between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Changes in levels of LDL-cholesterol
Average differences between time points for LDL-cholesterol will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Changes in levels of HDL-cholesterol
Average differences between time points for HDL-cholesterol will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Changes in levels of triglycerides
Average differences between time points for triglycerides will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.

Full Information

First Posted
May 8, 2014
Last Updated
September 18, 2017
Sponsor
Case Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT02135562
Brief Title
Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors
Official Title
A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
August 8, 2014 (Actual)
Primary Completion Date
April 19, 2017 (Actual)
Study Completion Date
April 19, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Case Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This pilot clinical trial studies protein-sparing modified fast (PSMF) intervention for weight loss in obese endometrial cancer survivors. The PSMF is a diet that is very low in carbohydrates and calories, designed to induce fast, safe weight loss. The diet consists of only lean meats (beef, pork, poultry, and seafood) in amounts adequate to meet protein requirements based on the individual's body weight. The PSMF may help endometrial cancer survivors achieve significant weight loss, reduce the risk of chronic disease, and improve quality of life.
Detailed Description
PRIMARY OBJECTIVES: I. Investigate whether the PSMF leads to significant weight loss in obese endometrial cancer survivors (ECS). II. To assess whether the approach is feasible, whether participants will remain in the study for the duration of the intervention while adhering to the various components of the protocol. To assess feasibility, examine the following variables: drop-out rates; rates of adherence to diet and supplemental protocol; and rates of common side-effects. III. Assess whether the PSMF improves biomarkers of disease risk in this population. To assess whether this objective has been met, assess the following variables: blood lipids (total cholesterol, low density lipid [LDL] cholesterol, high density lipid [HDL] cholesterol, and triglycerides); glucose; and markers of inflammation (C-reactive protein, interleukin-6, tumor necrosis factor [TNF]-alpha, and leptin). IV. Assess whether the PSMF leads to improvement in quality of life related to weight loss. OUTLINE: PSMF: Participants are instructed by a registered dietitian (RD) to consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight. The protein recommendation will be communicated to participants in terms of grams per day. Participants are encouraged to adhere as closely as possible to the protein recommendation. Based on the protein recommendation, participants are advised to consume a given amount (in ounces) of beef, pork, poultry and seafood daily, assuming that each ounce of these products contains seven grams of protein. Participants are provided with a digital kitchen scale to weigh protein-containing foods and are permitted up to 2 servings of non-starchy vegetables per day. Participants remain on the PSMF until they have successfully reduced their initial body weight by 15% or up to 6 months. Participants are also provided with supplements to consume daily. WEIGHT MAINTENANCE DIET: After successful weight loss of at least 15% of initial body weight, participants are instructed by a RD to consume a weight maintenance diet or they may remain on the PSMF. The weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the PSMF and consumption of non-starchy vegetables is unlimited. Participants receive handouts that list common foods and the number of carbohydrates in each serving and educated on nutrition label reading for carbohydrates, with emphasis on serving size and total number of carbohydrates per serving. After completion of study, participants are followed up at 2 and 4 weeks and then at 2, 3, 4, 5, and 6 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometrial Cancer, Obesity
Keywords
endometrial cancer, survivor, obesity, diet, high protein, protein-sparing modified fast intervention, PSMF

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Supportive Care (PSMF)
Arm Type
Experimental
Arm Description
Participants will take part in a Protein-Sparing Modified Fast (PSMF) Intervention for weight loss. Participants will undergo a dietary intervention high in protein for 6 weeks or until they have loss 15% of their body weight. This intervention will be followed by weight maintenance in which participants reintroduce non-starchy vegetables to their diet. At this time participants will also receive informational material and dietary education which teaches participants how to read nutrition labels and calculate carbohydrate loads in foods. Participants are given the Obesity and Weight-Loss Quality of Life Questionnaire to survey the impact of the intervention
Intervention Type
Dietary Supplement
Intervention Name(s)
Dietary Intervention
Other Intervention Name(s)
Dietary Modification, intervention, dietary
Intervention Description
Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.
Intervention Type
Other
Intervention Name(s)
Informational Material
Intervention Description
Receive carbohydrate reintroduction handout
Intervention Type
Other
Intervention Name(s)
Dietary Education
Other Intervention Name(s)
intervention, educational
Intervention Description
Receive education on nutrition label reading for carbohydrates
Intervention Type
Dietary Supplement
Intervention Name(s)
Weight Maintenance
Intervention Description
weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited
Intervention Type
Other
Intervention Name(s)
Average score of Obesity and Weight-Loss Quality of Life Questionnaire
Intervention Description
Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
Primary Outcome Measure Information:
Title
Mean Weight loss assessed with the digital scale
Description
Mean weight loss will be presented as mean total weight loss in kilograms from baseline
Time Frame
Baseline up to 6 months
Title
Mean Weight loss assessed with the digital scale
Description
Mean Weight loss will be presented as mean total weight loss in kilograms from baseline.
Time Frame
Baseline up to 12 months
Secondary Outcome Measure Information:
Title
Changes in levels of total cholesterol
Description
Average differences in total cholesterol between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Time Frame
Baseline up to 6 months
Title
Changes in levels of markers of inflammation (C-reactive protein)
Description
Average differences in C-reactive protein between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Time Frame
Up to 6 months
Title
Changes in levels of glucose
Description
Differences in glucose levels between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Time Frame
Up to 6 months
Title
Number of drop-out participants
Description
Presented as the difference in the number of participants who completed the study from the number of participants enrolled at baseline. This is reported as one of the markers of feasibility.
Time Frame
Up to 6 months
Title
Average percentage of positive urinary ketone tests as a marker of dietary adherence
Description
Assessed using the presence of urinary ketones beginning on day four of the intervention. Adherence rates will be presented as the percentage of positive urinary ketone tests for the duration of the intervention.
Time Frame
Up to 6 months
Title
Number of Participant with reported side effects
Description
Adverse events will be recorded by participants on a daily basis. Number of participants with related adverse events will be reported as one of the measures of feasibility
Time Frame
Up to 6 months
Title
Changes in quality-of-life as assessed by the Obesity and Weight Loss Quality-of-Life Questionnaire
Description
The difference between mean quality of life scores at the two time points will be assessed using a one-sided anova test with statistical significance set at p < 0.05.
Time Frame
Baseline up to 6 months
Title
Changes in levels of markers of inflammation (interleukin 6)
Description
Average differences in interleukin 6 between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Time Frame
Up to 6 months
Title
Changes in levels of markers of inflammation (tumor necrosis factor - alpha)
Description
Average differences in tumor necrosis factor - alpha between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Time Frame
Up to 6 months
Title
Changes in levels of markers of inflammation (leptin)
Description
Average differences of leptin between time points will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Time Frame
Up to 6 months
Title
Changes in levels of LDL-cholesterol
Description
Average differences between time points for LDL-cholesterol will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Time Frame
Baseline up to 6 months
Title
Changes in levels of HDL-cholesterol
Description
Average differences between time points for HDL-cholesterol will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Time Frame
Baseline up to 6 months
Title
Changes in levels of triglycerides
Description
Average differences between time points for triglycerides will be assessed using a one-sided anova test with statistical significance defined as having a p-value < 0.05.
Time Frame
Baseline up to 6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Previous diagnosis of endometrial cancer, successfully treated through surgery Body mass index (BMI) > 30 kg/m^2 > 8 weeks removed from surgery to treat endometrial cancer Exclusion Criteria: No previous diagnosis of endometrial cancer BMI < 30 kg/m^2 Any history of cardiovascular, kidney, or liver disease Using medication to treat diabetes History of cardiac arrhythmias Inability to comply with follow up regimen Inability to read or speak English Abstention from meat and other animal products
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kimberly Resnick
Organizational Affiliation
Case Comprehensive Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Medical Center, University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106-5065
Country
United States
Facility Name
MetroHealth Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44109
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors

We'll reach out to this number within 24 hrs